Skip to content

Author

Dina Khodeer

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Flavonoids: biological activities, nutritional and immunological aspects, therapeutic potential, food applications, and human health benefits—A comprehensive review

The global burden of infectious and non-communicable diseases presents a critical challenge, highlighting the urgent need for novel, safe, and effective therapies. Bioactive compounds from medicinal plants, especially flavonoids, offer a promising resource for drug discovery due to their diverse and potent pharmacological effects documented in preclinical studies. This comprehensive review summarizes current knowledge of flavonoids, including their classification into 14 main groups and their production via biosynthesis, chemical synthesis, modification, and extraction. While structural modification remains a key aspect of drug development, biosynthesis is increasingly seen as a potential transformative strategy for sustainable large-scale production. However, it requires a deeper understanding of metabolic pathways and optimization of synthetic methods. Aside from production challenges, a major translational hurdle is the inherently low bioavailability of many flavonoids. This review critically examines innovative solutions under investigation, such as advanced nanoparticles and colloidal drug delivery systems designed to address challenges in solubility, stability, and absorption. It also summarizes the current understanding of the mechanisms of action underlying their broad biological activities, primarily as evidenced by preclinical models, including nutritional, immunological, and disease-specific effects, and discusses potential drug interactions warranting clinical attention. Lastly, the review highlights key research gaps, including the need for more robust in vivo validation, standardized extracts to improve reproducibility, and well-designed clinical trials to verify efficacy in humans. Future directions include leveraging metabolic engineering and artificial intelligence to optimize biosynthesis, as well as targeted clinical studies of advanced delivery systems. By integrating these approaches, this review aims to establish a framework for ongoing research on flavonoids to inform future translational efforts that may eventually support their development as clinical therapies.

M. El-Saadony, A. Saad, Mohamed A. Fahmy et al. · 0 citations
Open access Aug 2026

Calycosin protects from histopathological and ultrastructural changes in ethanol-induced liver injury and exhibits predicted binding affinity to TNF-α/NF-κB/HIF-1α proteins

Background/objectives Liver fibrosis is the consequence of the wound-healing response of the liver to frequent injury. Calycosin is a flavonoid, which has been documented for its hepatoprotective properties. The aim of this study was to evaluate the hepatoprotective action of calycosin in a model of ethanol-induced liver injury (EILI) in rats. For mechanistic insights, we aimed to measure tumor necrosis factor-α (TNF-α), nuclear factor-κB (NF-κB), and hypoxia-inducible factor-1 alpha (HIF-1α) protein levels in liver samples and evaluate the ability of calycosin to bind these pathologic molecules. Methods Network pharmacology and molecular docking were performed for discovering the interacting target proteins. Forty male rats were assigned into five groups: 1) the vehicle, 2) the calycosin per se group, 3) the EILI control group, and 4) and 5) the EILI + calycosin (5 or 10 mg/kg) groups. The liver homogenates were used for ELISA measurement of TNF-α, NF-κB, and HIF-1α. Furthermore, liver specimens were used for histopathological and ultrastructural investigations. Results The network pharmacology study confirmed the role of TNF-α/NF-κB/HIF-1α signaling in EILI, and molecular docking explored the possible interaction between calycosin and these three molecules (docking score = −7.6, −7, and −7.6 kcal/mol). The rat study showed that calycosin was able to attenuate histopathological and ultrastructural changes in rat livers, reduce collagen accumulation, and prevent the increases shown in liver enzyme activities (2.17-fold for ALT and 2.26-fold for AST). Conclusion Thus, these integrated in silico and in vivo studies confirmed the hepatoprotective effect of calycosin against the EILI rat model and provided a mechanistic insight through TNF-α/NF-κB/HIF-1α signaling. Further studies are warranted to fully explore the protective mechanism of calycosin in EILI.

Abeer A. Mohamed, Y. G. Sabry, Amr El-Mistekawy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.